FY2025 Earnings Forecast for Avantor Issued By William Blair

Avantor, Inc. (NYSE:AVTR) – William Blair cut their FY2025 EPS estimates for Avantor in a research note issued to investors on Wednesday, October 29th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of $0.90 for the year, down from their prior forecast of $0.94. The consensus estimate for Avantor’s current full-year earnings is $1.06 per share. William Blair also issued estimates for Avantor’s Q4 2025 earnings at $0.21 EPS, Q1 2026 earnings at $0.22 EPS, Q2 2026 earnings at $0.24 EPS, Q3 2026 earnings at $0.23 EPS, Q4 2026 earnings at $0.24 EPS and FY2026 earnings at $0.93 EPS.

Avantor (NYSE:AVTR) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.01). Avantor had a positive return on equity of 10.91% and a negative net margin of 1.25%.The company had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.65 billion. During the same quarter in the prior year, the company posted $0.26 earnings per share. The business’s revenue was down 5.3% compared to the same quarter last year. Avantor has set its FY 2025 guidance at 0.880-0.920 EPS.

A number of other equities research analysts have also recently weighed in on the company. Barclays reaffirmed an “equal weight” rating and issued a $12.00 price objective (down from $15.00) on shares of Avantor in a research note on Thursday. Morgan Stanley cut their price target on shares of Avantor from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Monday, August 4th. Raymond James Financial increased their price target on shares of Avantor from $14.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, October 16th. Wells Fargo & Company dropped their price objective on shares of Avantor from $19.00 to $16.00 and set an “overweight” rating for the company in a report on Monday, August 4th. Finally, Royal Bank Of Canada cut their target price on shares of Avantor from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Monday, August 4th. Five investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat, Avantor currently has an average rating of “Hold” and an average price target of $14.42.

Avantor Stock Up 6.9%

Shares of NYSE AVTR opened at $11.82 on Friday. The company has a quick ratio of 0.67, a current ratio of 1.49 and a debt-to-equity ratio of 0.65. The business’s 50 day moving average is $13.33 and its two-hundred day moving average is $13.27. Avantor has a 52-week low of $10.82 and a 52-week high of $23.70. The firm has a market cap of $8.06 billion, a price-to-earnings ratio of -90.89, a PEG ratio of 3.81 and a beta of 0.98.

Insider Buying and Selling

In related news, CAO Steven W. Eck sold 3,476 shares of the firm’s stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $11.39, for a total value of $39,591.64. Following the sale, the chief accounting officer owned 55,068 shares of the company’s stock, valued at $627,224.52. This trade represents a 5.94% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gregory L. Summe purchased 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 30th. The stock was purchased at an average price of $11.25 per share, with a total value of $1,125,000.00. Following the purchase, the director directly owned 300,000 shares of the company’s stock, valued at $3,375,000. The trade was a 50.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Avantor

Hedge funds and other institutional investors have recently bought and sold shares of the business. Sector Gamma AS lifted its holdings in Avantor by 28.0% during the 3rd quarter. Sector Gamma AS now owns 477,104 shares of the company’s stock worth $5,954,000 after buying an additional 104,466 shares during the last quarter. Lightrock Netherlands B.V. raised its position in shares of Avantor by 10.5% during the 3rd quarter. Lightrock Netherlands B.V. now owns 555,380 shares of the company’s stock worth $6,931,000 after acquiring an additional 52,880 shares in the last quarter. Covestor Ltd lifted its stake in Avantor by 120.3% during the third quarter. Covestor Ltd now owns 13,026 shares of the company’s stock worth $162,000 after purchasing an additional 7,113 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Avantor by 11.8% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 19,534 shares of the company’s stock worth $263,000 after purchasing an additional 2,058 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Avantor by 28.0% in the third quarter. Massachusetts Financial Services Co. MA now owns 7,502,086 shares of the company’s stock valued at $93,626,000 after purchasing an additional 1,640,120 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.